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ABSTRACT
   Previous studies have highlighted marked inter-individual variations in factor VIII (FVIII) 
clearance between patients with haemophilia (PWH). The half-life of infused FVIII has been 
reported to vary from as little as 5.3 hours in some adult PWH, up to as long as 28.8 hours in 
other individuals. These differences in clearance kinetics have been consistently observed 
using a number of different plasma-derived and recombinant FVIII products. Furthermore, 
recent studies have demonstrated that half-life for extended half-life (EHL-) FVIII products 
also demonstrates significant inter-patient variation. Since time spent with FVIII trough levels 
less than 1% has been shown to be associated with increased bleeding risk in PWH on 
prophylaxis therapy, this variability in FVIII clearance clearly has major clinical significance. 
   Recent studies have provided significant novel insights into the cellular basis underlying 
FVIII clearance pathways. In addition, accumulating data have shown that endogenous 
plasma VWF levels, ABO blood group and age, all play important roles in regulating FVIII 
half-life in PWH. Indeed, multiple regression analysis suggests that together these factors 
account for approximately 34% of the total inter-individual variation in FVIII clearance 
observed between subjects with severe hemophilia A. In this review, we consider these and 
other putative modulators of FVIII half-life, and discuss the biological mechanisms through 
which these factors impact upon FVIII clearance in vivo.
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INTRODUCTION 
   Haemophilia A is an X-linked inherited bleeding disorder caused by deficiency or 
dysfunction of procoagulant factor VIII (FVIII). Approximately 25 in 100,000 male births are 
affected by hemophilia A.1 Consequently, there are estimated to be more than 1 million 
persons with hemophilia worldwide.1 Patients with severe hemophilia A (PWH) have plasma 
FVIII < 1 IU/dL (<1% normal). These individuals typically develop spontaneous bleeding in 
joints and muscles from early childhood which result in progressive musculoskeletal 
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FVIII replacement treatment. Several studies have confirmed that FVIII prophylaxis reduces 
the number of spontaneous joint bleeds, thereby significantly attenuating hemophilic 
arthropathy.2 
   Initial FVIII replacement studies first with single donations, and later with FVIII concentrates 
derived from human plasma, commenced in the 1950s based on the observation that 
spontaneous hemarthroses were much less common in patients with moderate hemophilia 
(FVIII 1 – 5 IU/dL; 1 – 5%). Thus, patients with severe hemophilia were treated with the aim 
of maintaining trough FVIII levels > 1%. From the 1990s, availability of recombinant FVIII 
products with standard half-life and later also modified FVIII with extended half-life enabled 
targeting higher trough levels of 3%, 5%, or even 10%, which could further reduce the 
likelihood of bleeding and might improve the  joint-health status of PWH.3,4. Based upon an 
estimated FVIII plasma half-life of approximately 12 hours, prophylaxis was typically 
administered as a dose of 25-40 IU/kg three times weekly. Critically however, accumulating 
data have demonstrated that this ‘one size fits all’ weight-based approach to hemophilia 
prophylaxis has inherent limitations.5 In particular, it is clear that in vivo clearance of FVIII 
varies markedly between different PWH.6,7 Despite this significant inter-individual variation in 
FVIII half-life, the mechanisms underlying FVIII clearance have remained poorly defined for 
many years. Recent studies have provided important insights into the biological mechanisms 
underpinning physiological and pathological FVIII clearance.8,9 In this manuscript, we review 
the molecular and cellular mechanisms responsible for modulating inter-individual variations 
in FVIII clearance in PWH, and consider its clinical significance. 
Inter-individual variation in FVIII clearance between PWH 
   Numerous pharmacokinetic (PK) studies have consistently demonstrated marked inter-
individual variations in FVIII clearance between PWH (Table 1).6,10-17 Collectively, these 
studies suggest that FVIII half-life may vary from as little as 5.3 hours in some PWH, up to as 
long as 28.8 hours in other individuals. These differences in clearance kinetics have been 
observed using a number of different plasma-derived and recombinant FVIII products 
(including full length and B-domain deleted rFVIII) and appear to be independent of the dose 
of FVIII administered.10-12 Moreover, similar inter-individual variations have been observed in 
studies of PWH from different ethnic and racial origins.14 FVIII clearance kinetics are 
significantly more rapid in young children compared to adult PWH.16,18 For example, 
Bjorkman et al found that the terminal half-life of FVIII in children aged 1-6 years was 9.4 
hours compared to 11.1 hours in a combined group of adolescents and adults (aged 10-65 
years).16 Nevertheless, significant inter-individual differences in FVIII clearance have also 
been reported in studies of pediatric cohorts.14,15 In contrast, for a given individual patient, 
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years.6,10,16,19 However, it has been shown that the half-life of infused FVIII is significantly 
reduced in PWH during acute bleeding episodes and in the perioperative period.20
FACTORS INFLUENCING INTER-INDIVIDUAL VARIATION IN FVIII CLEARANCE 
1. VWF levels and binding affinity
   Under normal conditions, the majority of plasma FVIII circulates in high affinity complex (Kd 
~ 0.2-0.5 nmol/L) with von Willebrand factor (VWF) (Figure 1).8,21 The plasma concentrations 
of FVIII and VWF are 200ng/ml (0.8nM) and 10µg/ml (35nM) respectively. Consequently, 
under steady-state conditions there is a 50 Molar excess of VWF. In normal individuals it has 
been estimated that approximately 95-97% of FVIII is bound to VWF, whilst the remaining 3-
5% circulates as free FVIII.8 Importantly however, this interaction between VWF and FVIII is 
reversible and exists as a dynamic equilibrium.22 Interaction with VWF plays an important 
role in protecting FVIII against premature proteolytic degradation and clearance. In the 
absence of VWF-binding, the half-life of free FVIII is reduced approximately 6-fold. This 
enhanced clearance underlies the reduced plasma FVIII levels typically seen in patients with 
Type 2N (characterized by reduced VWF binding to FVIII) or Type 3 VWD (almost complete 
VWF deficiency). Conversely, VWF half-life is not affected by the presence or absence of 
FVIII.
   Given this key role for VWF in regulating FVIII clearance in normal individuals, it is perhaps 
unsurprising that plasma VWF:Ag levels at time of FVIII treatment correlate with the half-life 
of infused FVIII. Several studies have demonstrated that FVIII half-life is significantly longer 
in PWH who have higher endogenous plasma VWF:Ag levels.10,12-15,17,21 This effect of VWF 
levels in regulating FVIII clearance is consistent for both pd- and rFVIII products.6,16 For 
example, in a study of 12 patients Fijnvandraat et al observed a strong correlation between 
pre-infusion VWF:Ag levels and half-life for a BDD-rFVIII product (r = 0.87; P = 0.0003).10 
Subsequently in a larger cohort of 32 PWH, Vlot et al confirmed a positive correlation 
between VWF:Ag levels and pd-FVIII half-life (r = 0.52; P = 0.001).11 Using linear regression 
analysis, the authors estimated that VWF levels accounted for approximately 25% of the total 
inter-patient variability observed in FVIII half-life.11 Calculations suggest that each increase of 
0.1 IU/dL VWF:Ag is associated with an increase of 16.6 (95% CI 9-24) minutes in the half-
life of infused FVIII (P < 0.01).12 Recent pediatric studies have showed that FVIII 
pharmacokinetics in children with haemophilia A are also significantly influenced by 
endogenous plasma VWF:Ag levels.14,15
   In addition to the importance of pre-infusion plasma VWF:Ag levels in regulating the half-















Turecek et al FVIII clearance variation in PWH 
This article is protected by copyright. All rights reserved
binding capacity of VWF may also contribute to inter-individual variations in FVIII clearance. 
Swystun et al investigated FVIII binding activity in 43 pediatric PWH.15 Sequencing of the 
FVIII-binding region of VWF identified five patients heterozygous for two low-frequency 
variants (p.Arg826Lys and p.Arg852Glu) both of which were shown to attenuate FVIII-
binding. Another study suggested that structural elements of the huge VWF protein chains 
and the degree of multimerization may influence FVIII binding.23 Collectively, these findings 
suggest that subtle reductions in the FVIII-binding capacity of endogenous VWF have the 
potential to lead to enhanced clearance of infused FVIII in PWH.  
2. ABO blood group
   Although traditionally regarded as red blood cell antigens, the carbohydrate structures that 
constitute the ABO blood group system (A, B and H determinants) are actually expressed on 
a number of other tissues and cell types including endothelial cells (EC) and platelets. 
Recent evidence suggests that the majority of plasma VWF and FVIII are derived from 
constitutive EC secretion. Prior to this secretion, VWF and FVIII undergo complex post-
translational modification that includes significant glycosylation.24 Unlike the vast majority of 
other plasma proteins, mass spectrometry studies have demonstrated that plasma VWF and 
FVIII both express covalently linked ABO(H) structures on their glycan structures. This is 
important because ABO blood group has a major effect on plasma levels of the VWF-FVIII 
complex. In particular, blood group O individuals have VWF:Ag levels that are approximately 
20-30% lower compared to non-O individuals.25 ABO group has similar effects on plasma 
FVIII:C levels in normal individuals, although these effects appear to be predominantly 
mediated via the changes in VWF levels. The mechanism(s) through which ABO blood group 
influences plasma VWF:Ag levels has not been fully elucidated, but current evidence 
suggests that VWF clearance is significantly enhanced in group O compared to non-O 
individuals.26 Interestingly, platelet VWF does not carry AB blood group determinants and 
levels are not influenced by ABO blood group.27
   Given the major effect of plasma VWF:Ag levels in determining the half-life of infused FVIII 
in PWH, it is perhaps unsurprising that several studies have reported that ABO blood group 
also influences FVIII pharmacokinetics.11,13,17 Vlot et al showed that FVIII half-life was 
significantly reduced in group O PWH compared to group A PWH (15.3 versus 19.7 hours 
respectively; P = 0.003).11 Similarly, Fischer et al observed significantly enhanced FVIII 
clearance in group O compared to non-O adult PWH (11.5 versus 14.3 hours; P = 0.004).13 
This later study further observed that plasma VWF:Ag levels correlated more strongly with 
FVIII half-life in non-O compared to group O PWH. Despite the fact that ABO blood group 
prevalence varies between racial groups, the ABO effect in modulating FVIII clearance in 
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ethnicities. Finally, although FVIII clearance is significantly faster in children compared to 
adult PWH,18 nonetheless an ABO effect on FVIII half-life is still apparent in pediatric PK 
studies.14,15 
3. Age
   It is well recognized that plasma VWF:Ag levels increase progressively with age. This 
observation has been reported in normal individuals, as well as in patients with VWD.28,29 
Indeed, plasma VWF:Ag levels have been shown to correct into the normal range with 
advancing age in many patients with mild quantitative VWD.30 Furthermore, significant age-
related increases in plasma VWF levels have also been observed in PWH. van Dijk et al 
demonstrated that every ten years increase in age in PWH was associated with a 0.16 IU/dL 
increase of in VWF:Ag levels.12 Interestingly, the age-related increase in plasma VWF:Ag has 
also been reported to be more marked in non-O compared to group O individuals.28 
   Since endogenous VWF levels have an effect in regulating infused FVIII half-life in PWH, 
several groups have investigated whether age may also have an effect. Some inconsistency 
in results has been observed between studies, which may reflect limited sample numbers, as 
well as other differences in study design. Nevertheless, a number of studies have reported 
that FVIII clearance is reduced in older patients.11,13,17,19 For example, Vlot et al observed a 
trend towards increased FVIII half-life with age, although this failed to achieve statistical 
significance (P = 0.08).11 In addition, Fischer et al demonstrated a weak positive correlation 
between age and FVIII half-life on univariate analysis (Pearson-rank = 0.5; P = 0.028).13 
More recently, Kepa et al also showed that age had a significant association with FVIII 
clearance. When patients were grouped into age decades, the authors noted that this age 
effect was considerably more evident in PWH aged greater than 40 years.17 Importantly, 
regression analysis confirmed that the association between age and FVIII clearance was not 
just attributable to increased VWF levels, as age remained an independent predictor even 
following correction for VWF. Although the biology underlying this age-related increase in 
VWF has not been fully defined, recent data suggest that age may impact upon both the 
secretion and clearance of VWF.28
4. Additional factors
   It is well established that neutralizing high-titer FVIII-specific antibodies in PWH result in 
the rapid clearance of infused FVIII. These polyclonal antibodies tend to be IgG1 or IgG4 and 
are high-affinity in nature.31 Non-neutralizing anti-FVIII antibodies can also be identified in a 
significant number of PWH who do not have clinically evident inhibitors.32 These antibodies 
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42 adult PWH, Hofbauer et al investigated whether these non-neutralizing FVIII-specific 
antibodies had any effect on the clearance of infused FVIII.33 Overall, 15 (37%) of these 
patients studied were found to have FVIII-binding antibodies with titers ≥ 1:20. Moreover, in 9 
of these subjects, the titer of FVIII-specific antibodies was ≥ 1:40. Interestingly, FVIII half-life 
was significantly reduced in this cohort with high titer non-neutralizing FVIII-specific 
antibodies (median 7.8 versus 10.4 hours respectively; P = 0.004). The effect of the non-
neutralizing antibodies was independent of VWF:Ag levels and was estimated to account for 
17% of the total inter-individual variability in FVIII half-life.33
   The fact that ABO blood group influences FVIII clearance has led to the suggestion that 
other blood groups may also be important. Vlot et al found that Rhesus phenotype (RhD), a 
blood group system determined by a protein in the red blood cell membrane, had no effect 
on FVIII pharmacokinetics in PWH.11 In contrast, the Secretor carbohydrate blood group 
shares some similarities with the ABO system in that it is defined by the presence or absence 
of specific terminal sugar residues on glycan chains. A number of groups have reported a 
weak association between Secretor blood group and plasma VWF:Ag levels.34,35 Further 
studies will be required to determine whether this effect on VWF levels translates into a 
secondary effect on FVIII half-life in PWH. Finally, studies have investigated whether FVIII 
PK may be influenced by FVIII genotype in PWH.17 However, no significant difference in FVIII 
recovery or clearance were observed between patients with F8 gene inversions, deletions or 
point mutations respectively. 
Clearance of free-FVIII compared to VWF-bound FVIII 
   As previously discussed, under normal steady state conditions, approximately 95-97% of 
plasma FVIII circulates bound to VWF.8,36 The remaining 3-5% circulates in plasma as free-
FVIII. Consequently, it seems likely that the majority of infused FVIII in PWH will be cleared 
in complex with endogenous VWF. Importantly, although the amount of free-FVIII in plasma 
at any particular time point is limited, this fraction of FVIII has a very short in vivo half-life (~2 
hours compared to ~12 hours for VWF-bound FVIII). Consequently, as much as 25% of total 
infused FVIII in PWH may actually be cleared in the form of free-FVIII.37 The relative 
proportion of infused FVIII cleared as free-FVIII will clearly be highly dependent upon the 
affinity of the FVIII-VWF binding interaction (Figure 2). 
   Recent studies have provided significant insights into the biological pathways involved in 
regulating the clearance of both free-FVIII and VWF-bound FVIII.8,9 These data have 
demonstrated that hepatic macrophages and liver sinusoidal EC (LSECs) play key roles in 
regulating in vivo clearance of VWF and FVIII.38-40 In addition, a number of cell surface 
receptors have also been implicated in modulating VWF-FVIII binding interactions.9 On 
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the scavenger receptor class A member I (SR-A1)42 and the macrophage galactose-type 
lectin (MGL).43 Additional receptors expressed on LSECs that may be important include 
stabilin-2 (STAB2)40 and C-type lectin domain family 4 member M (CLEC4M).44 A number of 
other miscellaneous receptors have also been reported to bind FVIII in vitro. These include 
the asialoglycoprotein receptor (ASGPR) which is predominantly expressed on hepatocytes, 
as well as LDL-R, CD206, Siglec-5 and heparin sulfate proteoglycans (HSPGs).8 Although 
the relative importance of these different clearance receptors in terms of regulating the 
clearance of free- and VWF-bound FVIII remains unclear, many of them have been shown to 
be able to bind and internalize VWF and FVIII. Interestingly, for some of these clearance 
receptors (e.g. LRP1 and ASGPR), the ability of FVIII to interact with the receptor is 
significantly attenuated when FVIII is in complex with VWF.8 Nevertheless, significant 
correlations between some receptor polymorphisms and human FVIII levels have been 
reported.45,46 In addition, Lunghi et al recently reported that a polymorphism in the LDLR 
(c.1773C/T) was associated with differences in the initial phase of FVIII distribution in PWH.47 
All together, based on current evidence, it seems that variation in clearance pathways for 
free- and VWF-bound FVIII are highly likely to contribute to inter-individual variations in FVIII 
clearance in PWH (Figure 2).9,48
Inter-individual variations in VWF clearance pathways 
   As detailed above, current findings suggest that VWF represents the most important 
determinant of inter-individual variation in FVIII clearance in PWH. In keeping with this 
hypothesis, the effects of ABO blood group and age on FVIII half-life seem to result 
predominantly via their respective effects upon VWF levels. The observation that pre-infusion 
plasma VWF:Ag levels positively correlates with FVIII half-life in PWH is interesting. One 
simple explanation for this correlation would be that in PWH with higher endogenous VWF 
levels, more infused FVIII therapy is able to bind to VWF.13 Consequently, since there is less 
free-FVIII in plasma, overall FVIII clearance rate is attenuated. A number of lines of evidence 
suggest that this may not be the case. First, VWF is present in huge molar excess in plasma 
compared to the infused FVIII.36 Second, several studies have demonstrated that induced 
increases in plasma VWF levels prior to FVIII infusion do not affect FVIII half-life in 
hemophiliac plasma. In a murine model of hemophilia, Fischer et al showed that treatment 
with rIL-11 resulted in a 1.7-fold increase in plasma VWF levels compared to untreated 
controls.13 Subsequently, the half-life of infused FVIII was assessed in the rIL-11 treated and 
control cohorts. Despite the higher basal VWF levels in the rIL-11 treated group, no 
difference in FVIII half-life was observed.13 Similarly, human studies have shown that DDAVP 
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However, DDAVP pre-treatment two hours prior to infusion of FVIII had no significant effect 
on FVIII clearance.49 
Some plasma derived FVIII concentrates also contain VWF in substantial and 
pharmacologically relevant amounts. Nevertheless, pharmacokinetics of such FVIII-VWF 
concentrates seem not to be essentially different from pharmacokinetics of FVIII products 
devoid of VWF. Both groups of products, plasma-derived with and without VWF and 
recombinant FVIII concentrates, all without VWF are considered to have virtually 
indistinguishable pharmacokinetics of FVIII.14,50 
   An alternative mechanism that could explain the positive correlation between plasma VWF 
levels and FVIII half-life in PWH is that the VWF level is really a surrogate measure of 
endogenous VWF clearance rates. Hence, PWH with slower VWF clearance rates will tend 
to have higher basal plasma VWF:Ag levels. According to this hypothesis, these PWH would 
also have longer FVIII half-lives since the majority of infused FVIII is cleared through VWF-
dependent clearance pathways. This mechanism is consistent with the data demonstrating 
that targeted increased in plasma VWF levels before FVIII administration do not prolong FVIII 
half-life.13,49 Several studies have attempted to assess endogenous VWF clearance rates in 
PWH using VWF propeptide to antigen (VWF:pp/VWF:Ag) ratios. Swystun et al recently 
reported a strong association between FVIII pharmacokinetics in PWH and the 
VWF:pp/VWF:Ag ratio (P < 0.0001).15 In particular, the VWF:pp/VWF:Ag ratio negatively 
correlated with FVIII half-life in non-O pediatric PWH.15 Similarly, Fischer et al observed a 
strong correlation between VWF:pp/VWF:Ag ratio and FVIII half-life in blood group O PWH 
(Pearson-rank = 0.7; P = 0.001).13 Collectively, these findings emphasize the fact that FVIII 
half-life in PWH is critically dependent upon inter-individual variations in clearance rates for 
endogenous VWF. The factors responsible for regulating variability in VWF clearance 
between individual patients with haemophilia remain to be defined but likely relate in part to 
(i) variations in VWF glycosylation51,52 and/or (ii) variations in VWF clearance pathways.9,48
Variation in FVIII clearance – clinical significance 
   Understanding the molecular mechanisms responsible for the marked inter-individual 
variability in FVIII clearance kinetics observed between individual PWH has major clinical 
significance. In particular, Collins et al demonstrated that for patients with severe hemophilia 
A on prophylaxis, increasing time per week with plasma FVIII less than 1% was associated 
with significantly increased risk for bleeding episodes.18 This finding was true for both 
hemarthroses and total bleeds. Moreover, the observation was consistent for both children 
and adult PWH. For example, in 99 patients aged between 10 and 65 years, each hour spent 
with FVIII levels below 1% were associated with a 1.4% increase in annual bleed rate (CI 















Turecek et al FVIII clearance variation in PWH 
This article is protected by copyright. All rights reserved
of infusions are critical determinants of the amount of time each PWH spends per week with 
trough FVIII levels < 1%.7 In contrast, in vivo FVIII recovery and infused FVIII dose per kg 
were less important. Cumulatively, these data have led to the concept that personalized 
treatment regimens for PWH should be considered. Defining individual-specific FVIII PK 
parameters constitutes a critical first step in terms of developing any precision-medicine 
approach to the treatment of hemophilia. This approach has already been investigated in a 
number of clinical studies and has been become significantly more practical with the recent 
introduction of population-based PK studies. This subject has been addressed in a number of 
recent comprehensive review articles.53,54 
   With respect to optimization of treatment for PWH, it is also important to highlight that a 
number of different extended half-life (EHL-) rFVIII treatments have been developed in recent 
years that use a variety of different genetic engineering strategies to extend the half-life of 
FVIII.55 Interestingly however, significant inter-individual variation in clearance of these long-
acting FVIII preparations has already been reported.56-58 In the clinical context, knowledge of 
individual pharmacokinetics for EHL-FVIII is likely to be of even greater translational 
importance.59 Although the biological factors responsible for mediating inter-individual 
variation in clearance of different EHL-rFVIII products remains poorly understood, it is 
interesting that associations with endogenous plasma VWF levels and ABO blood group 
have already been reported.57,60 These data are consistent with the concept that EHL-FVIII 
molecules are still being cleared in complex with endogenous VWF.
Conclusions
   In conclusion, numerous studies have highlighted the fact that marked inter-individual 
variation in FVIII clearance rates exists between PWH. This variation has direct clinical 
relevance in that it impacts the efficacy of weight-based FVIII prophylaxis regimens.12 Current 
state-of-the-art data suggest that endogenous VWF levels, ABO blood group and age all play 
important roles in regulating FVIII half-life in PWH. Critically however, multiple regression 
analysis suggests that cumulatively VWF, ABO group and age can only explain 34% of the 
total inter-individual variation in FVIII clearance observed between subjects with severe 
hemophilia A.17 Further adequately powered studies that include deep clinical phenotype, 
detailed PK analysis and genomic data will be necessary to elucidate the biological 
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LEGENDS
Table 1: Examples of studies investigating FVIII half-life determinants in PWH
n = number. 
Figure 1: FVIII interaction with VWF in normal plasma.
VWF and FVIII are both expressed in EC and secreted into plasma. Normal plasma 
concentrations for VWF and FVIII are 35nM and 0.8nM respectively. The majority of plasma 
FVIII (approximately 95-97%) circulates as part of a high affinity complex with VWF. Thus. 
free-FVIII and VWF-bound FVIII exists in dynamic equilibrium. 
Figure 2: Inter-individual variation in FVIII clearance in PWH
Previous studies have highlighted marked inter-individual variations between PWH in terms 
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insights into the cellular and receptors involved in the clearance of both free-FVIII and VWF-
bound FVIII, the biological mechanisms responsible for the variation in FVIII half-life remains 
poorly understood. This may be due to (i) variability in the VWF-FVIII binding affinity*; (ii) 
variation in the clearance of Free-FVIII**  and/or (3) variation in the clearance of VWF-bound 
FVIII*** 
LSECs = liver sinusoidal endothelial cells; STAB2 = stabilin-2; CLEC4M = C-type lectin 
domain family 4 member M; MGL = macrophage galactose-type lectin; LRP1 = low-density 
lipoprotein receptor-related protein-1; SR-A1 = scavenger receptor class A member I; 
ASGPR = asialoglycoprotein receptor.
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